Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH104 for Pruritus in Primary Biliary Cholangitis
NCT06733519Phase 2Not yet recruiting
- Sponsor
- Tharimmune, Inc.
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of nalmefene in pruritus (2 arms), sponsored by Tharimmune, Inc. Primary endpoint: Safety and tolerability of repeat doses of TH104 at 42 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
nalmefene
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT06733519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733519.